Clinical trial
Fetched
Post
clinicaltrials.gov
Zynerba Pharmaceuticals, Inc.
(2018).
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX).
ClinicalTrials.gov.
Zynerba Pharmaceuticals, Inc..
- Publication date
-
12 Jun 2018
- Identifier
-
NCT03614663
- Authors
-
Zynerba Pharmaceuticals, Inc.
- Source
- ClinicalTrials.gov
- Reference type
- clinical_trial
- Publisher
- Zynerba Pharmaceuticals, Inc.
- Metadata source
- clinicaltrials.gov
Abstract
This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome (FXS). Eligible participants will then participate in up to a 14 week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \< 18 years, will be eligible to participate.